Results 61 to 70 of about 18,928 (205)

Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations [PDF]

, 2015
Patient registries play an important role in cardiology. They provide data not found in randomised controlled trials, including valuable information on drug use and clinical outcomes.
Cambou, Claeys, Gevaert, Matter, Zeymer, Zeymer, Zeymer   +6 more
core   +1 more source

P‐CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with atherothrombotic disease on antithrombotic therapy, P‐CABs demonstrated a significantly superior protective effect against clinically significant upper GI haemorrhage compared to PPIs (aHR 0.22; p = 0.016). This real‐world study highlights P‐CABs as a more potent gastroprotective strategy for high‐risk populations requiring intensive ...
Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim, Suna Yu, Eui Sun Jeong, Chung Hyun Tae   +6 more
wiley   +1 more source

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
Background Few studies have examined how antiplatelet therapies are selected during the routine care of acute myocardial infarction patients, particularly relative to the patient's estimated mortality and bleeding risks.
Amit N. Vora, Eric D. Peterson, Lisa A. McCoy, Mark B. Effron, Kevin J. Anstrom, Douglas E. Faries, Marjorie E. Zettler, Gregg C. Fonarow, Brian A. Baker, Gregg W. Stone, Tracy Y. Wang   +10 more
doaj   +1 more source

Cancer event rate and mortality with thienopyridines: a systematic review and meta-analysis [PDF]

, 2016
Introduction Thienopyridines are a class of antiplatelet drugs widely used in cardiovascular disease prevention and treatment. A recent concern has come to light regarding the safety of thienopyridines because of the possible risk of malignancy.
Kinnaird, T, Kontronias, RA, Kwok, CS, Mamas, M, Wong, C, Zaman, A   +5 more
core   +2 more sources

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Prasugrel for the treatment of patients with acute coronary syndrome

Vascular Health and Risk Management, 2009
Filippo Marzot, Vittorio PengoClinical Cardiology, Thrombosis Centre, University of Padua, ItalyAbstract: Prasugrel (CS-747, LY640315) is a novel member of the thienopyridine class of oral anti-platelet agents (also including ticlopidine and clopidogrel).
Filippo Marzot, Vittorio Pengo
doaj  

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis

Health Technology Assessment, 2015
Background: Acute coronary syndromes (ACSs) are life-threatening conditions associated with acute myocardial ischaemia. There are three main types of ACS: ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (
Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Nigel Fleeman, Joanne McEntee, Yenal Dundar, Marty Richardson, Michael Fisher   +9 more
doaj   +1 more source

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis

Frontiers in Cardiovascular Medicine, 2022
BackgroundThis meta-analysis mainly aimed to compare the impact of prasugrel and ticagrelor on platelet reactivity (PR) in patients with acute coronary syndrome (ACS).MethodsWe searched four electronic databases to identify randomized controlled trials ...
Lulu Dai, Jiawei Xu, Yuerong Jiang, Keji Chen   +3 more
doaj   +1 more source

Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring [PDF]

, 2017
Aims: Dual platelet inhibition using anti-P2Y12 drugs and aspirin is the standard of care in patients after percutaneous coronary interventions (PCI). Prasugrel and ticagrelor have been shown to be more potent than clopidogrel with less high on-treatment
Bernard Vrijens, Chin B. Eap, Chin B. Eap, Eric Eeckhout, Eric Tousset, Grégoire Wuerzner, Isabelle Bassi, Isabelle Menetrey, Michel Burnier, Olivier Muller, Pierre Fontana, Pierre Fontana, Valentina Forni Ogna   +12 more
core   +3 more sources

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source